10 recruiting, 8 active not recruiting, 3 completed, 2 not yet recruiting. 15 Phase 2, 7 Phase 3, 5 Phase 1, 1 Early Phase 1, 1 Not applicable.
Follow calaspargase pegol: new trials by email Literature Review of calaspargase pegol trials Research Report on calaspargase pegol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 90 | 2026-10-14 | 2026-10-13 |
| Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Children's Oncology Group | 1708 | 2026-08-28 | 2026-07-30 |
| A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy) Decitabine, Venetoclax, Calaspargase pegol-mknl - T-cell Acute Lymphoblastic Leukemia, T-Cell Lymphoblastic Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 22 | 2025-09-25 | 2026-09-18 |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 153 | 2025-06-05 | 2026-10-27 |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy - B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 222 | 2025-05-30 | 2026-10-27 |
| Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma Dexamethasone, Vincristine, Inotuzumab - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 128 | 2025-01-23 | 2026-07-16 |
| Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) Dexamethasone, Vincristine, Daunorubicin - T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 100 | 2024-12-27 | 2026-08-10 |
| Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2024-08-09 | 2024-05-17 | |
| A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia Biospecimen Collection, Bone Marrow Aspiration, Calaspargase Pegol - Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | Children's Oncology Group | 78 | 2024-01-08 | 2026-08-25 |
| Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma Biospecimen Collection, Calaspargase Pegol, Levocarnitine - B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 3 | Active not recruiting | Children's Oncology Group | 440 | 2023-08-24 | 2026-08-21 |
| CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy), Calaspargase Pegol, Rituximab - Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 7 | 2023-05-01 | 2026-03-06 |
| Venetoclax Basket Trial for High Risk Hematologic Malignancies Venetoclax, Azacitidine, Cytarabine - Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary | Phase 1 | Recruiting | Andrew E. Place, MD | 30 | 2023-03-29 | 2026-03-12 |
| Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax Venetoclax, Navitoclax, Dexamethasone - Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 35 | 2022-08-25 | 2026-10-15 |
| Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer Biopsy, Calaspargase Pegol-mknl, Cobimetinib - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 1 | Completed | OHSU Knight Cancer Institute | 15 | 2022-08-09 | 2026-07-23 |
| Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Diagnosed AML Calaspargase pegol-mknl - Acute Myeloid Leukemia | Phase 1 | Active not recruiting | West Virginia University | 6 | 2021-09-27 | 2026-09-02 |
| SPARK-ALL: Calaspargase Pegol in Adults With ALL Calaspargase pegol (S95015) - Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Terminated | Institut de Recherches Internationales Servier | 42 | 2021-07-07 | 2026-10-29 |
| A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) 3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection - Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 461 | 2020-12-17 | 2026-11-12 |
| Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma | Phase 3 | Recruiting | Children's Oncology Group | 5951 | 2019-10-31 | 2026-08-25 |
| Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma Methotrexate, pralatraxate,, Ifosfamide - NK-Cell Lymphoma, NK-Cell Leukemia | Early Phase 1 | Recruiting | New York Medical College | 40 | 2019-03-01 | 2026-08-18 |
| Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide - Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia | Phase 3 | Active not recruiting | Children's Oncology Group | 352 | 2017-08-08 | 2026-10-05 |
Showing 20 of 25. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (11) · Burkitt Lymphoma (9) · Leukemia, Biphenotypic, Acute (8) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (8) · Leukemia (2) · Lymphoma (2) · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (2) · Down Syndrome (1) · Leukemia, Large Granular Lymphocytic (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Peripheral (1) · Myelodysplastic Syndromes (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1)
Children's Oncology Group (8) · National Cancer Institute (NCI) (4) · St. Jude Children's Research Hospital (4) · Andrew E. Place, MD (1) · Dana-Farber Cancer Institute (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Institut de Recherches Internationales Servier (1) · M.D. Anderson Cancer Center (1) · New York Medical College (1) · OHSU Knight Cancer Institute (1) · SWOG Cancer Research Network (1) · West Virginia University (1)
United States (21) · Canada (7) · Puerto Rico (6) · Australia (5) · New Zealand (2) · Austria (1) · Belgium (1) · Chile (1) · Czechia (1) · Finland (1) · France (1) · Germany (1) · Hong Kong (1) · Israel (1) · Italy (1)
Andrea Biondi (1) · Andrew E Place, MD, PhD (1) · Andrew Place, MD (1) · Anne L Angiolillo (1) · Ashkan Emadi, MD, PhD (1) · Bijal Shah, MD (1) · Charles D Lopez (1) · Dale J. Pullen, MD (1) · Daniel J. DeAngelo, MD, PhD (1) · David McCall, MD (1) · Erin H Breese (1) · Etan Orgel (1) · Hiroto Inaba, MD, PhD (1) · Ibrahim Aldoss (1) · Jennifer L McNeer (1)
PMID 41671463, PMID 35622074, PMID 30626253, PMID 33026184, PMID 34228505, PMID 35007127, PMID 36625831, PMID 38446568, PMID 41074700, PMID 41619724, PMID 42154791
U10CA180886 (8), U10CA180888 (2), 2017 (1), U10CA030969 (1), U10CA098543 (1), U24CA196173 (1), UG1CA189955 (1)